Blog - Announcements

Vasomedical Announces Second Quarter 2016 Financial Results

Revenue and Operating Income Grew Year-Over-Year by 68% and 28%, Respectively

PLAINVIEW, NY / ACCESSWIRE / August 15, 2016 / Vasomedical, Inc. (“Vasomedical”) (OTC PK: VASO) today reported its operating results for the three months ended June 30, 2016.

“We are pleased to report that the Company recorded $18.2 million of total revenue during the second quarter of 2016, a 68% increase from the same quarter a year ago, due mainly to the inclusion of the NetWolves operations we acquired at the end of May 2015 as well as the growth in the healthcare IT VAR (value added resale) business we started in late 2014. Our proprietary equipment business unit also saw significant growth and improvement during the quarter,” commented Dr. Jun Ma, President and Chief Executive Officer of Vasomedical, Inc. “Adjusted EBITDA was $886 thousand and $1.6 million for the three- and six-month period ending June 30, respectively, compared to $751 thousand and $729 thousand for the same periods last year, representing a growth of 18% and 119% year-over-year. We also recorded improvement in net income for the second quarter and first half of 2016. Given this momentum as well as our historical trend of being more profitable in the second half of the year, we feel confident in delivering the third consecutive year of profitability in 2016.”

“It is exciting to see significant revenue growth from our healthcare IT VAR operations in the second quarter of 2016. Moreover, the substantial backlog in this business unit continues to grow, and our team is working hard to turn it into revenue and profit as we accelerate the implementation of the underlying IT services for the customers,” concluded Dr. Ma.

Three Months Ended June 30, 2016 Financial Results

For the three months ended June 30, 2016, revenue increased by 68% to $18.2 million from $10.8 million for the same period of 2015. This is primarily attributable to an increase of $7.3 million of revenue in our IT segment, $6.5 million of which was from the NetWolves subsidiary the Company acquired in the end of May 2015, and an increase of $841 thousand, or 1781%, in our healthcare IT VAR business. Additionally, equipment segment revenue increased 23% to $1.2 million.

Gross profit for the second quarter of 2016 increased 38% to $10.1 million, compared with $7.3 million for the second quarter of 2015. The increase was principally due to the increase of $2.8 million in the IT segment, including $2.7 million from our NetWolves operations, and an increase of $258 thousand in our equipment segment, offset by a slightly lower gross profit in our professional sales services segment.

Selling, general and administrative (SG&A) expenses for the second quarter of 2016 increased to $9.7 million from $7.0 million for the second quarter last year. The increase is primarily due to including three months of the NetWolves operations in the quarter, compared to only one month of NetWolves operations for the second quarter 2015.

Operating income for the second quarter 2016 was $264 thousand, compared to $206 thousand for the same period in 2015, representing an increase of 28%. The improvement in operating income was due to the increase in gross profit and lower SG&A expenses relative to revenue. SG&A expenses were 53% of revenues for the quarter ended June 30, 2016, compared to 64% of revenues for the same period in 2015. Net income for the three months ended June 30, 2016 was $213 thousand, compared with net income of $191 thousand for the three months ended June 30, 2015, an increase of 12%.

Adjusted EBITDA (earnings before interest, taxes, depreciation and amortization and non-cash stock-based compensation) rose to $0.9 million for the three months ended June 30, 2016, compared to $0.8 million for the same period a year ago, representing an increase of 18%.

Net cash generated from operating activities in the first half of 2016 was $3.7 million. As of June 30, 2016, the Company had cash and cash equivalents of approximately $5.6 million, compared to cash and cash equivalents of $2.2 million at December 31, 2015. We anticipate continued positive cash flows from operations for the remainder of the year.

Conference Call Information

The Company will host a conference call on Monday, August 15, 2016 at 11:00 a.m. ET featuring remarks by Jun Ma, Ph.D., President and CEO, Peter Castle, Chief Operating Officer, and Michael Beecher, Chief Financial Officer of Vasomedical. To join the conference call, please dial 1-877-407-8033 from the U.S. or 1-201-689-8033 internationally. Please call at least five minutes before the scheduled start time. The conference call will also be available via webcast and can be accessed through the Investor Relations section of Vasomedical’s website, Please allow extra time prior to the call to visit the site and download any necessary software to listen to the live broadcast.

Link to Yahoo Finance: